Chimeric Therapeutics Insider Buys AU$800k Worth of Shares at AU$0.008 per Share, 11% Ownership by Insiders

Chimeric Therapeutics Limited insiders have been net buyers, with the largest purchase being AU$800k by Founder & Executive Chairman Paul Hopper. The company's insiders own AU$990k worth of shares, representing 11% of the company.

Chimeric Therapeutics Limited (CHM), a biotech company focused on developing chimeric antigen receptor (CAR) T-cell therapies, has seen notable insider activity. The company's insiders, including Founder & Executive Chairman Paul Hopper, have been net buyers, with the largest purchase being AU$800,000. Currently, insiders own AU$990,000 worth of shares, representing 11% of the company [1].

In terms of valuation, CHM's Price-To-Sales (PS) Ratio stands at 4.6x, which is significantly below the Australian Biotechs industry average of 14.1x. However, when compared to its peers, CHM's PS Ratio is slightly higher than the average of 4.5x. This indicates that CHM is undervalued based on its PS Ratio compared to the industry average but may be overvalued relative to its peers [1].

Key valuation metrics for CHM include its Enterprise Value/Revenue of 2.1x and Enterprise Value/EBITDA of -0.3x. The PEG Ratio is not applicable due to CHM's unprofitability. Analysts have not provided sufficient data for a price forecast, making it challenging to assess the consensus price target [1].

In conclusion, while CHM's insiders have shown confidence in the company by increasing their shareholdings, its valuation metrics suggest it may be undervalued relative to the industry average but overvalued compared to its peers. Further data and analysis are needed to provide a more comprehensive assessment.

References:
[1] https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-chm/chimeric-therapeutics-shares/valuation